180 Wealth Advisors LLC purchased a new stake in shares of Fortress Biotech, Inc. (NASDAQ:FBIO – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 62,350 shares of the biopharmaceutical company’s stock, valued at approximately $107,000. 180 Wealth Advisors LLC owned about 0.31% of Fortress Biotech as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also modified their holdings of FBIO. Choreo LLC acquired a new stake in Fortress Biotech in the fourth quarter valued at approximately $109,000. Gladstone Institutional Advisory LLC acquired a new stake in shares of Fortress Biotech in the 4th quarter worth $36,000. Armistice Capital LLC purchased a new position in Fortress Biotech during the 4th quarter worth $1,794,000. PVG Asset Management Corp acquired a new position in Fortress Biotech during the 4th quarter valued at about $396,000. Finally, Shikiar Asset Management Inc. raised its stake in Fortress Biotech by 21.8% in the first quarter. Shikiar Asset Management Inc. now owns 223,136 shares of the biopharmaceutical company’s stock valued at $446,000 after buying an additional 40,000 shares during the last quarter. 96.51% of the stock is currently owned by institutional investors.
Fortress Biotech Stock Performance
FBIO traded up $0.09 during trading on Thursday, reaching $1.90. 413,933 shares of the company’s stock were exchanged, compared to its average volume of 311,420. The company’s fifty day simple moving average is $1.92 and its 200-day simple moving average is $1.89. The stock has a market capitalization of $38.78 million, a P/E ratio of -0.31 and a beta of 1.74. The company has a debt-to-equity ratio of 38.42, a current ratio of 1.33 and a quick ratio of 1.21. Fortress Biotech, Inc. has a 1 year low of $1.24 and a 1 year high of $7.35.
Insider Transactions at Fortress Biotech
In related news, CEO Lindsay A. Md Rosenwald purchased 20,000 shares of Fortress Biotech stock in a transaction that occurred on Friday, June 28th. The stock was bought at an average cost of $1.64 per share, for a total transaction of $32,800.00. Following the completion of the transaction, the chief executive officer now owns 2,893,905 shares in the company, valued at $4,746,004.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Lindsay A. Md Rosenwald purchased 20,000 shares of the company’s stock in a transaction that occurred on Friday, June 28th. The shares were bought at an average price of $1.64 per share, for a total transaction of $32,800.00. Following the completion of the transaction, the chief executive officer now owns 2,893,905 shares in the company, valued at $4,746,004.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Lindsay A. Md Rosenwald acquired 5,000 shares of the firm’s stock in a transaction on Thursday, July 11th. The stock was purchased at an average price of $7.48 per share, with a total value of $37,400.00. Following the transaction, the chief executive officer now owns 127,500 shares of the company’s stock, valued at approximately $953,700. The disclosure for this purchase can be found here. Insiders have purchased 30,500 shares of company stock worth $110,700 over the last quarter. 33.40% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on the company. StockNews.com upgraded Fortress Biotech from a “sell” rating to a “hold” rating in a research note on Wednesday. Roth Mkm reissued a “buy” rating and set a $10.00 target price on shares of Fortress Biotech in a research report on Thursday, May 16th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Fortress Biotech in a report on Thursday, June 20th. Finally, HC Wainwright reissued a “buy” rating and set a $24.00 price objective on shares of Fortress Biotech in a report on Friday, July 19th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $28.50.
Check Out Our Latest Stock Report on Fortress Biotech
About Fortress Biotech
Fortress Biotech, Inc, a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne.
Featured Stories
- Five stocks we like better than Fortress Biotech
- Insider Buying Explained: What Investors Need to Know
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- What is Insider Trading? What You Can Learn from Insider Trading
- Jeff Brown’s Exegesis AI Stock Picks
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Want to see what other hedge funds are holding FBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fortress Biotech, Inc. (NASDAQ:FBIO – Free Report).
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.